- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Corporate and Securities Litigation
- E-Discovery
- Global Construction and Infrastructure Disputes
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Lauren K. Roth
News 6 results
In the News · Source: Law360 Healthcare Authority
January 13, 2026
Lauren Roth provides analysis regarding the decrease in FDA guidance during President Trump's administration
In the News · Source: Law360 Healthcare Authority
December 2, 2025
Lauren Roth comments on the Food and Drug Administration’s uptick of pilot programs launched this year
In the News · Source: PharmaVoice
In the News · Source: Medtech Insight
January 23, 2025
Lauren Roth discusses how states are navigating AI compliance and regulations
Press Release
January 15, 2025
Lauren Roth, Former Leader of FDA’s Office of Policy, Joins King & Spalding’s FDA and Life Sciences Team
In the News · Source: Law360, Bloomberg Law, Reuters, POLITICO Influence, POLITICO Playbook, Thomson Reuters Westlaw Today, Attorney at Law Magazine, JDJournal, The Daily Docket and The National Law Journal
January 15, 2025
Lauren Roth, former U.S. Food and Drug Administration Associate Commissioner for Policy, joins the firm’s FDA and Life Sciences team in Washington, D.C.